Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17836988 | 1.00 | CYP19A1 (0.64) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041382 | 0.86 | CYP19A1 (0.66) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041205 | 0.85 | CYP19A1 (0.64) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039735 | 0.84 | CYP11B2 (0.58) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1040981 | 0.82 | CYP11B2 (0.62) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041670 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041342 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL27861938 | 0.82 | CYP11B2 (0.62) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL732525 | 0.82 | CYP11B2 (0.43) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1041691 | 0.81 | CYP19A1 (0.59) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176883-A1 | Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176883-A1 | Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | CYP21A2, CYP19A1, NR5A1 | CYP19A1 2/4885CYP11B2 15/4885CYP11B1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.